<DOC>
	<DOC>NCT03106844</DOC>
	<brief_summary>In this study we will evaluate patients with IBD and and atleast 2 confirmed c.difficile infections who will be undergoing FMT. We will assess patients before FMT and then follow patients prospectively post FMT at week 1, 8 and 12 to assess for recurrence of c.difficile infection and IBD outcomes.</brief_summary>
	<brief_title>The ICON Study: Outcomes After FMT for Patients With IBD and CDI</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<criteria>Adults age 18 or greater Confirmed recurrent CDI by positive PCR or EIA toxin test defined at ≥ 2 episodes and vancomycin failure within one year with the most recent being within the past 3 months. Confirmed diagnosis of IBD with colonic involvement (ulcerative colitis, Crohn's colitis or ileocolitis or indeterminate colitis) for ≥ 3 months Undergoing FMT via colonoscopy for CDI as part of standard medical care Unable or unwilling to undergo a colonoscopy Inpatient status Anticipated immediate or upcoming surgery within 30 days Need for continued nonantiCDI antibiotic therapy History of total or subtotal proctocolectomy Isolated ileal or small bowel disease Pregnancy or lactation Female patients who are pregnant or breastfeeding or plan to become pregnant in the next 6 months. Patients who are unable to give informed consent Participation in a clinical trial in the preceding 30 days or simultaneously during this trial Severe food allergy (anaphylaxis or anaphylactoidlike reaction) Life expectancy &lt; 6 months Unable to adhere to protocol requirements Any condition that the physician investigators deems unsafe, including other conditions or medications that the investigator determines that it will put the subject at greater risk from FMT Known concurrent HIV, Hepatitis B or C infection Concurrent PSC Patients with WBC&lt; 3.0 x109th/L at baseline Patients with platelet count &lt; 100 x109th/L Patients with initial elevation of AST or ALT &gt; 1.5 times above normal limit at baseline Non steroidal antiinflammatory medications (NSAIDs) as longterm treatment, defined as use for at least 4 days a week each month Treatment with vancomycin or metronidazole for more then 60 days prior to enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>FMT</keyword>
	<keyword>IBD</keyword>
</DOC>